



Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details


Unit NAV	RM3.2099
Fund Size	RM68.3 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

Top 10 Holdings

Pentamaster	8.9%
Dufu Technology	8.8%
Frontken	8.4%
Duopharma Biotech	7.5%
Thong Guan	4.8%
Pharmaniaga	4.4%
Power Root	4.0%
FoundPac Group	3.8%
OCK Group	3.2%
Solarvest	3.0%

Data as at 31 July 2020

Cumulative Performance Since Inception as at 31 July 2020




Performance Table as at 31 July 2020

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	16.0%	27.4%	9.8%	6.8%	22.5%	23.7%	56.0%	575.8%
Benchmark	8.2%	16.4%	4.8%	0.8%	-1.5%	-9.1%	-4.0%	94.6%

- Benchmark: FTSE Bursa Malaysia Emas Index
- Source: Bloomberg & Gibraltar BSN Life Bhd

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 31 July 2020



Source: UOBAM



Manager's Comment

For July 2020, the Fund's NAV/unit increased by 16.0%, outperformed the FBM EMAS which increased by 8.2% due to stock selection especially the Fund's position in technology and healthcare stocks. Technology stocks in the Fund outperformed on long term structural trends such as digitalization and 5G. In the healthcare sector, the Fund's holding in Duopharma rallied on news that the company was chosen by the government for vaccine bottling of the Covid-19 vaccine when it is available.

Despite a resurgence in new Covid-19 cases globally and escalating US-China tensions, sentiment was lifted by hopes of fresh stimulus and better-than-expected recovery seen in mainland China. Meanwhile, the US reported a 9.5% yoy contraction in its GDP for 2Q20.

On the domestic front, the FBM KLCI gained 6.8% in July, posting its fourth consecutive month of gains. Bank Negara Malaysia (BNM) cut the overnight policy rate (OPR) by 25bps in July, bringing the OPR to a historic low of 1.75%. Besides that, the Malaysian government announced a 3-month extension to the existing loan moratorium and additional financial assistance for targeted groups. The financial aid is expected to benefit 3 million individuals and businesses who have been affected by the Covid-19 pandemic.

Meanwhile, the FBM Small Cap Index gained 10% to close at 13,051 points. Brent oil futures gained 5.2% to close at US\$43/bbl while CPO price surged 16.5%. The Ringgit strengthened against the US Dollar by 1.1% to close at 4.24.

Looking ahead, we have a neutral view on equities in the near term in view of the increasing uncertainties and the strong recovery in equities since bottoming in March. Hence, we plan to keep relatively higher cash levels for mispricing opportunities in the event of a market sell down. Our preferred sectors include IT (semiconductor) and healthcare.

For Internal Use Only

Disclaimer

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at www.gibraltarsbn.com for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.